| Drug ID: | Drug169 |
|---|---|
| Drug Name: | SAR443122 |
| CID: | 130298939 |
| DrugBank ID: | DB16492 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT05588843 |
| Molecular Formula: | C19H18N6O3 |
| Molecular Weight: | 378.4 g/mol |
| Isomeric SMILES: | CN1C(=O)[C@H](COC2=C1N=CC=C2)NC(=O)C3=NNC(=N3)CC4=CC=CC=C4 |
| Synonyms: | Eclitasertib; 2125450-76-0; DNL758; Eclitasertib [INN]; Eclitasertib [USAN]; SAR443122; DNL-758; 975AT1P9J6; UNII-975AT1P9J6; SAR-443122 |
| Phase 0: | 0 |
| Phase 1: | 1 |
| Phase 2: | 2 |
| Phase 3: | 0 |
| Phase 4: | 0 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05588843 | Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis | PHASE2 | RECRUITING | Sanofi | Colitis Ulcerative | DRUG: SAR443122|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations